Abstract
Estimating epidemiological parameters is essential for informing an effective public health response during waves of infectious disease transmission. However, many parameters are challenging to estimate from real-world data, and rely on human challenge studies or mass community testing. During Winter 2023/2024, a community cohort study of SARS-CoV-2 was conducted across households in England and Scotland. From this survey, questionnaire data and follow-up testing protocols provided valuable data into multiple epidemiological parameters: namely, the duration of positivity, test sensitivity, and the incubation period. Here, Bayesian statistical modelling methods are developed and applied to estimate the underlying parameters. The duration of LFD positivity is found to increase with increasing age, with a mean of 8.55 days (95% CrI: 7.65 days, 9.44 days) in the youngest age group compared to 10.27 days (95% CrI: 9.85 days, 10.71 days) in the oldest age group. Similarly, test sensitivity, as a function of time since symptom onset, decays fastest in the youngest age group, reaching a minimum sensitivity of 0.26 (95% CrI: 0.16, 0.37) compared to 0.54 (95% CrI: 0.46, 0.6). Such patterns are expected since younger individuals experience less severe symptoms of COVID-19 and are likely to clear the virus faster. Combining the duration of positivity and test sensitivity, we estimate the probability of returning a positive test. Close to symptom onset date, this probability is approximately 95%. However, this rapidly drops off, dropping below 5% after 11.3 days (95% CrI: 9.7 days, 13 days) for the youngest age group and 16.2 days (95% CrI: 15.4 days, 17.1 days) for the oldest age group. For the incubation period, there is no clear pattern by age. Across all age groups, the mean incubation period is 2.52 days (95% CrI: 2.42 days, 2.62 days). This is shorter than the most recent estimates for Omicron BA.5, which is in line with earlier research that found replacing variants had shorter incubation periods.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There was no financial support for this work, completed as part of the authors employment.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
National Statisticians Data Ethics Advisory Committee of UK Statistics Authority gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Stan code for all models and trace files from the MCMC samplers are available at https://github.com/OvertonC/winter_covid_infection_study-parameters. UKHSA operates a robust governance process for applying to access protected data that considers: -the benefits and risks of how the data will be used -compliance with policy, regulatory and ethical obligations -data minimisation -how the confidentiality, integrity, and availability will be maintained -retention, archival, and disposal requirements -best practice for protecting data, including the application of privacy by design and by default, emerging privacy conserving technologies and contractual controls Access to protected data is always strictly controlled using legally binding data sharing contracts. UKHSA welcomes data applications from organisations looking to use protected data for public health purposes. To request an application pack or discuss a request for UKHSA data you would like to submit, contact DataAccess{at}ukhsa.gov.uk.
https://github.com/OvertonC/winter_covid_infection_study-parameters
